201 related articles for article (PubMed ID: 16237740)
1. Treatment of advanced endocrine gastroenteropancreatic tumours using radiolabelled somatostatin analogues.
Van Eijck CH
Br J Surg; 2005 Nov; 92(11):1333-4. PubMed ID: 16237740
[No Abstract] [Full Text] [Related]
2. Treatment of endocrine gastroenteropancreatic tumors with somatostatin analogues.
Fehmann HC; Wulbrand U; Arnold R
Recent Results Cancer Res; 2000; 153():15-22. PubMed ID: 10626286
[TBL] [Abstract][Full Text] [Related]
3. [New therapeutic strategies in gastroenteropancreatic neuroendocrine tumours].
Colao A; Pulcrano M; Dorato M; Müller F; Rossi FW; De Martino MC; Biondi B; Lombardi G
Minerva Endocrinol; 2001 Dec; 26(4):231-8. PubMed ID: 11782708
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues.
Kwekkeboom DJ; Teunissen JJ; Kam BL; Valkema R; de Herder WW; Krenning EP
Hematol Oncol Clin North Am; 2007 Jun; 21(3):561-73; x. PubMed ID: 17548040
[TBL] [Abstract][Full Text] [Related]
5. Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives.
Capurso G; Fazio N; Festa S; Panzuto F; De Braud F; Delle Fave G
Crit Rev Oncol Hematol; 2009 Nov; 72(2):110-24. PubMed ID: 19249226
[TBL] [Abstract][Full Text] [Related]
6. Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis.
Burgess JR; Greenaway TM; Parameswaran V; Shepherd JJ
Cancer; 1999 Nov; 86(10):2154-9. PubMed ID: 10570446
[TBL] [Abstract][Full Text] [Related]
7. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].
Uomo G; Germano D; Rabitti PG
Minerva Endocrinol; 2001 Dec; 26(4):225-9. PubMed ID: 11782707
[TBL] [Abstract][Full Text] [Related]
8. The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors.
Trautmann ME; Neuhaus C; Lenze H; Benning R; Benning M; Dennler HJ; Bruns C; Joseph K; Arnold R
Horm Metab Res Suppl; 1993; 27():24-7. PubMed ID: 8392487
[No Abstract] [Full Text] [Related]
9. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours.
Angeletti S; Corleto VD; Schillaci O; Marignani M; Annibale B; Moretti A; Silecchia G; Scopinaro F; Basso N; Bordi C; Delle Fave G
Gut; 1998 Jun; 42(6):792-4. PubMed ID: 9691916
[TBL] [Abstract][Full Text] [Related]
10. [Somatostatin receptors in meningioma: diagnostic and therapeutic value].
Prat R; Banzo J; Díaz FJ
Rev Neurol; 1997 Dec; 25(148):2002-5. PubMed ID: 9528047
[TBL] [Abstract][Full Text] [Related]
11. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors.
Degen L; Beglinger C
Digestion; 1999; 60 Suppl 2():9-14. PubMed ID: 10207226
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
Butturini G; Bettini R; Missiaglia E; Mantovani W; Dalai I; Capelli P; Ferdeghini M; Pederzoli P; Scarpa A; Falconi M
Endocr Relat Cancer; 2006 Dec; 13(4):1213-21. PubMed ID: 17158766
[TBL] [Abstract][Full Text] [Related]
13. [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].
Simonenko VB; Dulin PA; Makanin MA
Klin Med (Mosk); 2006; 84(4):4-8. PubMed ID: 16755846
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological treatment of gastroenteropancreatic apudomas with an analog of somatostatin, SMS 201-995 (octreotide)].
Varas Lorenzo MJ
Rev Esp Enferm Dig; 1991 Feb; 79(2):95-8. PubMed ID: 2059523
[TBL] [Abstract][Full Text] [Related]
15. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours.
Shah T; Caplin M
Best Pract Res Clin Gastroenterol; 2005 Aug; 19(4):617-36. PubMed ID: 16183531
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of the expression of somatostatin receptors in digestive endocrine tumours.
Capurso G; Panzuto F; Delle Fave G
Dig Liver Dis; 2010 Mar; 42(3):173-4. PubMed ID: 20117969
[No Abstract] [Full Text] [Related]
17. [Biotherapy of neuroendocrine tumours of the gastrointestinal tract and pancreas].
Hansen CP; Knigge U
Ugeskr Laeger; 2008 Jun; 170(24):2145-8. PubMed ID: 18565299
[TBL] [Abstract][Full Text] [Related]
18. [Contribution of synthetic somatostatin analogues to the clinical features of gastroenteropancreatic endocrine tumors].
Biliotti G
G Chir; 2006 Apr; 27(4):129-31. PubMed ID: 16768865
[No Abstract] [Full Text] [Related]
19. [Therapy of endocrine gastrointestinal-pancreatic tumors with somatostatin analog octreotide].
Arnold R; Neuhaus C; Trautmann ME
Dtsch Med Wochenschr; 1992 Jul; 117(27):1067-71. PubMed ID: 1352235
[No Abstract] [Full Text] [Related]
20. 111In-octreotide scintigraphy: a tool to select patients with endocrine pancreatic tumors for octreotide treatment?
Keymeulen B; Bossuyt A; Peeters TL; Somers G
Ann Nucl Med; 1995 Aug; 9(3):149-52. PubMed ID: 8534589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
